LP

LB Pharmaceuticals Inc Common Stock

LBRX·NASDAQ

$27.95

+3.4%
HealthcareBiotechnology

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

At a Glance

Live Snapshot
Market Cap$801.51M
EPS-1.0000
P/E Ratio-27.95
Earnings Date06/25/2026

lbrx

Total Debt

Last Annual Value

3.57M

3-Year CAGR

-47%

5-Year CAGR

-32%

10-Year CAGR

-17%

LP

LB Pharmaceuticals Inc Common Stock Competitors Analysis of Total Debt

LBRX · NASDAQ
CompanyTotal Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
3.57M
N/AN/AN/A 
17.38M
-3.9%77.9%N/A
ANNX logo
Annexon, Inc.
NASDAQ:ANNX
26.20M
-5.8%-5.4%N/A
76.71M
16.5%23.8%8.1%
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
64.85M
4.1%4.8%N/A
29.03M
47.3%39.2%N/A
41.92M
-12.8%-9.2%N/A
76.17M
7.8%18.0%N/A
10.83M
-4.5%-7.2%N/A
24.88M
-0.2%1.9%-6.5%
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
43.49M
9.4%-0.9%N/A
LP

LB Pharmaceuticals Inc Common Stock Fair Value Envelope

LBRX · NASDAQ

Our analysis suggests that LBRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.95, this represents a potential HIDDEN relative to our calculated worth for LB Pharmaceuticals Inc Common Stock.

Intrinsic Value
Current Price: $27.95